In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 3, 2009, Pages 169-177

  van Giersbergen, P L M ^a   Treiber, A ^a   Dingemanse, Jasper ^a  

^a Actelin Pharmaceuticals Ltd   (Switzerland)

Author keywords

Clazosentan; Distribution; Endothelin receptor antagonist; Excretion; Metabolism

Indexed keywords

CLAZOSENTAN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450; DIOXANE DERIVATIVE; ENDOTHELIN A RECEPTOR; ISOENZYME; PLASMA PROTEIN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TETRAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG URINE LEVEL; DYSPEPSIA; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INSECT CELL; MALE; NONHUMAN; NORMAL HUMAN; OPEN STUDY; BLOOD; CHEMISTRY; DRUG ANTAGONISM; FECES; GENETICS; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PROTEIN BINDING; TISSUE DISTRIBUTION; URINE;

ADULT; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DIOXANES; FECES; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; ISOENZYMES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROTEIN BINDING; PYRIDINES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; SULFONAMIDES; TETRAZOLES; TISSUE DISTRIBUTION;

EID: 65549123573     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47169     Document Type: Article

References (22)

1. Aithal GP, Day CP, Kesteven PJL, Daly AK. Relationship of polymorphisms in the cytochrome P450 CYP2C9 to warfarin dose requirements and risk of bleeding complications. Lancet. 1999; 353: 717-719.
2. Binet I, Wallnöfer A, Weber C, Jones R, Thiel G. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 2000; 57: 224-231.
3. Crespi CL, Stresser DM. Fluorimetric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Meth. 2000; 44: 325-331.
4. Daly AK, Steen VM, Fairbrother KS, Idle KS Jr. CYP2D6 multiallelism. Meth Enzymol. 1996; 272: 199-210.
5. Dorsch NWC, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage. J Clin Sci. 1994 1: 19-26.
6. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
7. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab. 2004; 5: 21-53.
8. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005; 77: 1-16.
9. Macdonald LR, Kakarieka A, Mayer S, Pasqualin A, Ruefenacht D, Schmiedek P, Kassell NF. Prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage with clazosentan, an endothelin receptor antagonist. Istanbul, Turkey. 9th International conference on cerebral vasospasm. Abstract OP5-3; 2006.
10. Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet. 1989; 2: 1402.
11. Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL. Fluorimetric high-throughput screening for inhibitors of cytochrome P450. Ann N Y Acad Sci. 2000; 919: 26-32.
12. Omvik P, Tarazi RC, Bravo EL. Determination of extracellular fluid volume in uremic patients by oral administration of radiosulfate. Kidney Int. 1979; 15: 71-79.
13. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997; 283: 1110-1118.
14. Rowland M, Tozer TN. Clinical pharmacokinetics - Concepts and applications. Baltimore-Tokyo: Williams and Wilkins; 1995.
15. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenet. 1996; 6: 341-348.
16. Treiber A, van Giersbergen PLM, Dingemanse J. In vitro and in vivo disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans. Xenobiotica. 2003; 4: 399-414.
17. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled multicenter Phase IIa study. J Neurosurg. 2005; 103: 9-17.
18. Van Giersbergen PLM, Bodin F, Dingemanse J. Cyclosporine increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol. 2002; 58: 243-245.
19. Van Giersbergen PLM, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol. 2007; 63: 151-158.
20. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenet. 1995; 5: 37-42.
21. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999; 27: 810-815.
22. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415.